Home > Offer to Sell > Pharmaceuticals and Biochemicals > Antineoplastics agents > Sorafenib tosylate
Sorafenib tosylate
Inquiry
| Post Date: | Jan 22,2018 |
| Expiry Date: | Jan 22,2019 |
| Detailed Description: |
Cas No. :475207-59-1;4750207-59-1
Quantity: 80Kilograms Specs:Not less than 98% on dried basis Payment Method: Negotiable Anticancer medicine used to treat a certain type of liver, kidney or thyroid cancer called: Hepatocellular carcinoma (HCC, a type of liver cancer), when it cannot be treated with surgery Renal cell carcinoma (RCC, a type of kidney cancer) Differentiated thyroid carcinoma (DTC, a type of thyroid cancer) that can no longer be treated with radioactive iodine and is progressing. |
| CAS Registry Number: | 475207-59-1;4750207-59-1 |
| Synonyms: | ;SORAFENIB-D3;4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate;N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate;Sorafenib TsOH salt; |
| Molecular Formula: | C21H16ClF3N4O3·C7H8SO |
| Molecular Weight: | 637.03 |
| Molecular Structure: | 
|
| Company: | Shandong Langnuo Pharmaceutical Co., Ltd. [ China ] |
| Contact: | Jacqueline |
| Tel: | +86-531-88116033 |
| Fax: | +86-531-88115352 |
| Email: | export@bestcomm.cn |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
